Syntex (u.s.a.) Inc.

Philip Jay Teitelbaum

Keith Adrian Walker

David Bruce Repke

Roger L Whiting

Owen W Gooding

Gregory Ricardo Martinez

The present invention relates to novel benzocycloalkylazolethione compounds which are dopamine .beta.-hydroxylase inhibitors in which the benzocycloalkyl portion of the compound is selected from indanyl, 1,2,3,4-tetrahydronaphthalenyl and 6,7,8,9-tetrahydro-5H-benzocycloheptenyl (in which the benzo is optionally substituted with one to three substituents) and the azolethione portion of the compound is selected from 2-thioxo-2,3-dihydro-1H-imidazol-3-yl, 5-thioxo-4,5-dihydro-1H-�1,2,4!triazol-4-yl and 5-thioxo-4,5-dihydro-1H-�1,2,4!triazol-1-yl (each optionally substituted with one to three substituents); and the prodrugs, pharmaceutically acceptable salts, individual isomers and mixtures of isomers and the methods of using and preparing such benzocycloalkylazolethione compounds.

Growing community of inventors

Boulder Creek, CA, United States of America

Philip Jay Teitelbaum